ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Dallas, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Dallas, TX, USA:

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).FDA has approved selinexor plus dexamethaso ...

Enrolling
Plasma Cell Myeloma
Myeloma, Plasma Cell
Drug: Selinexor
Drug: Daratumumab

Phase 2

US Oncology Network
US Oncology Network

Fort Worth, Texas, United States and 9 other locations

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

Dallas, Texas, United States and 25 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Dallas, Texas, United States and 145 other locations

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Active, not recruiting
Multiple Myeloma
Myeloma
Drug: Cyclophosphamide
Drug: Bendamustine

Phase 1

Fate Therapeutics
Fate Therapeutics

Dallas, Texas, United States and 13 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

Dallas, Texas, United States and 9 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Dallas, Texas, United States and 31 other locations

a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...

Enrolling
Relapsed/ Refractory Multiple Myeloma
Biological: GC012F (AZD0120)

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Dallas, Texas, United States and 12 other locations

Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple...

Enrolling
Multiple Myeloma
Drug: CLN-619

Phase 1

Cullinan Therapeutics Inc.

Dallas, Texas, United States

1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: zevor-cel

Phase 1, Phase 2

CARsgen Therapeutics

Dallas, Texas, United States and 12 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Dallas, Texas, United States and 59 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems